Results 101 to 110 of about 8,209 (210)

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Vedolizumab Induces Remission in Two Cases of Ulcerative Colitis With Upper Gastrointestinal Involvement

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Ulcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy.
Shinya Nakatani, Yuta Yamazaki, Kensuke Higuchi, Yumi Otoyama, Norihiro Suzuki, Kazuo Kikuchi, Takahisa Fujiwara, Atsushi Katagiri, Jyun Ohara, Hitoshi Yoshida   +9 more
wiley   +1 more source

Severe and disseminated atypical mycobacteriosis of the skin under immunosuppression

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Veronika Zenderowski, Laura Schreieder, Mark Berneburg, Dennis Niebel, Sebastian Haferkamp, Sigrid Karrer, Konstantin Drexler   +6 more
wiley   +1 more source

Severe Gastroduodenitis Associated With Ulcerative Colitis After Total Colectomy Successfully Treated With Endoscopic Hemostasis and Oral Tacrolimus

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Herein, we report a rare case of gastroduodenitis associated with ulcerative colitis (UC). A 42‐year‐old man was diagnosed with UC 1 year prior to admission to our hospital. The patient underwent a 3‐stage total colectomy and ileal pouch‐anal anastomosis for severe UC.
Koji Fujimoto, Shuhei Hosomi, Yumie Kobayashi, Rieko Nakata, Yu Nishida, Fumio Tanaka, Yasuhiro Fujiwara   +6 more
wiley   +1 more source

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature

Drugs in Context
Upadacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of different rheumatic diseases, including axial spondyloarthritis (axSpA).
Giuseppe Lopalco, Arianna D’Antonio, Maria Sole Chimenti, Florenzo Iannone   +3 more
doaj   +1 more source

Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn's disease in the UK: a multicentre retrospective cohort study. [PDF]

OBJECTIVE: Upadacitinib is the first Janus kinase inhibitor and oral advanced therapy licensed for Crohn's disease (CD). Following NICE approval in 2023, real-world data on outcomes are limited. The effectiveness and safety of upadacitinib in a cohort of

core   +1 more source

Modern Strategies in the Pharmacotherapy of Inflammatory Bowel Diseases – A Literature Review [PDF]

Introduction and Aim:Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic, immune-mediated disorders of the gastrointestinal tract.
Boral, Aleksandra, Brzoza, Joanna, Czarnecki , Bartłomiej, Górski, Michał, Koczur, Julia, Kryś, Dominika, Kurkiewicz, Wojciech, Pniok, Wiktoria, Werenkowicz, Wiktor   +8 more
core   +1 more source

Elastolytic Granulomatous Dermatoses: Toward a Unified Clinicopathological Concept

International Journal of Dermatology, EarlyView.
Rose Kathrin Caroline Moritz, Christiane Michl, Sonja Leson   +2 more
wiley   +1 more source